Dr. Olga Kubassova on Forbes Podcast

In a recent Forbes podcast, Dr. Olga Kubassova, CEO of IAG, Image Analysis Group, shared groundbreaking insights on how artificial intelligence is revolutionizing clinical trials and drug development. This discussion is a must-listen for pharmaceutical and biotech leaders looking to optimize their R&D processes.

Key Takeaways for Drug Developers:

1. Structured Real-Time Data: Learn how IAG’s approach to data management can significantly reduce decision-making timelines in your clinical trials.

2. Modern Trial Infrastructure: Discover how DYNAMIKA, IAG’s proprietary cloud-based platform, can streamline your clinical operations and enhance data quality.

3. Smart Technologies: Explore how AI-driven imaging analysis can provide early efficacy assessments, potentially saving millions in development costs.

4. Risk Mitigation: Understand how IAG’s predictive analytics can help de-risk your clinical development process.

5. Accelerated Time-to-Market: Hear how IAG’s innovative approaches have helped bring lifesaving therapies to patients faster.

Dr. Kubassova’s insights come at a crucial time when the pharmaceutical industry is seeing a 700% increase in the use of imaging in clinical trials over the past decade. IAG’s expertise in this rapidly growing field could be the key to giving your drug development program a competitive edge.

Don’t miss this opportunity to learn how IAG’s cutting-edge solutions can transform your clinical trials. Listen to the full podcast on Forbes Books, Apple, or Spotify.